Literature DB >> 31256636

Evaluation and Management of the Child and Adult With Fontan Circulation: A Scientific Statement From the American Heart Association.

Jack Rychik, Andrew M Atz, David S Celermajer, Barbara J Deal, Michael A Gatzoulis, Marc H Gewillig, Tain-Yen Hsia, Daphne T Hsu, Adrienne H Kovacs, Brian W McCrindle, Jane W Newburger, Nancy A Pike, Mark Rodefeld, David N Rosenthal, Kurt R Schumacher, Bradley S Marino, Karen Stout, Gruschen Veldtman, Adel K Younoszai, Yves d'Udekem.   

Abstract

It has been 50 years since Francis Fontan pioneered the operation that today bears his name. Initially designed for patients with tricuspid atresia, this procedure is now offered for a vast array of congenital cardiac lesions when a circulation with 2 ventricles cannot be achieved. As a result of technical advances and improvements in patient selection and perioperative management, survival has steadily increased, and it is estimated that patients operated on today may hope for a 30-year survival of >80%. Up to 70 000 patients may be alive worldwide today with Fontan circulation, and this population is expected to double in the next 20 years. In the absence of a subpulmonary ventricle, Fontan circulation is characterized by chronically elevated systemic venous pressures and decreased cardiac output. The addition of this acquired abnormal circulation to innate abnormalities associated with single-ventricle congenital heart disease exposes these patients to a variety of complications. Circulatory failure, ventricular dysfunction, atrioventricular valve regurgitation, arrhythmia, protein-losing enteropathy, and plastic bronchitis are potential complications of the Fontan circulation. Abnormalities in body composition, bone structure, and growth have been detected. Liver fibrosis and renal dysfunction are common and may progress over time. Cognitive, neuropsychological, and behavioral deficits are highly prevalent. As a testimony to the success of the current strategy of care, the proportion of adults with Fontan circulation is increasing. Healthcare providers are ill-prepared to tackle these challenges, as well as specific needs such as contraception and pregnancy in female patients. The role of therapies such as cardiovascular drugs to prevent and treat complications, heart transplantation, and mechanical circulatory support remains undetermined. There is a clear need for consensus on how best to follow up patients with Fontan circulation and to treat their complications. This American Heart Association statement summarizes the current state of knowledge on the Fontan circulation and its consequences. A proposed surveillance testing toolkit provides recommendations for a range of acceptable approaches to follow-up care for the patient with Fontan circulation. Gaps in knowledge and areas for future focus of investigation are highlighted, with the objective of laying the groundwork for creating a normal quality and duration of life for these unique individuals.

Entities:  

Keywords:  AHA Scientific Statements; Fontan procedure; congenital heart defects; quality of life

Year:  2019        PMID: 31256636     DOI: 10.1161/CIR.0000000000000696

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  88 in total

1.  Routine Surveillance Catheterization is Useful in Guiding Management of Stable Fontan Patients.

Authors:  Neil D Patel; Patrick M Sullivan; Arash Sabati; Allison Hill; Chelsea Maedler-Kron; Shengmei Zhou; Nick Shillingford; Roberta Williams; Cheryl Takao; Sarah Badran
Journal:  Pediatr Cardiol       Date:  2020-01-24       Impact factor: 1.655

2.  Acute Hemodynamic Effects of Negative Extrathoracic Pressure in Fontan Physiology.

Authors:  David M Peng; Jeffrey D Zampi; Susan M Smith; Sunkyung Yu; Nichole Rottach; Ray Lowery; Heang M Lim; Lori Q Riegger; Kurt R Schumacher; Albert Rocchini
Journal:  Pediatr Cardiol       Date:  2019-08-29       Impact factor: 1.655

Review 3.  Heart failure in single right ventricle congenital heart disease: physiological and molecular considerations.

Authors:  Anastacia M Garcia; Jonathan-Thomas Beatty; Stephanie J Nakano
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-02-28       Impact factor: 4.733

4.  Relationship of Ventricular Morphology and Atrioventricular Valve Function to Long-Term Outcomes Following Fontan Procedures.

Authors:  Jiyong Moon; Li Shen; Donald S Likosky; Vikram Sood; Reilly D Hobbs; Peter Sassalos; Jennifer C Romano; Richard G Ohye; Edward L Bove; Ming-Sing Si
Journal:  J Am Coll Cardiol       Date:  2020-07-28       Impact factor: 24.094

5.  Higher Incidence of Protein-Losing Enteropathy in Patients with Single Systemic Right Ventricle.

Authors:  Alyssa M Bernardi; Sylvestor Moses; Brent J Barber; Marlys H Witte; Michael D Seckeler
Journal:  Pediatr Cardiol       Date:  2020-09-25       Impact factor: 1.655

Review 6.  The failing Fontan.

Authors:  T K Susheel Kumar
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2020-03-07

7.  Computational Modeling of Right Ventricular Motion and Intracardiac Flow in Repaired Tetralogy of Fallot.

Authors:  Yue-Hin Loke; Francesco Capuano; Elias Balaras; Laura J Olivieri
Journal:  Cardiovasc Eng Technol       Date:  2021-06-24       Impact factor: 2.495

Review 8.  Fontan Circulation Might be Associated with Peripartum Cardiomyopathy: A Review of Mechanistic and Clinical Aspects.

Authors:  Kenan Yalta; Ertan Yetkin; Gokay Taylan
Journal:  Curr Cardiol Rev       Date:  2021

9.  Is Doppler Echocardiography Adequate for Surgical Planning of Single Ventricle Patients?

Authors:  Zhenglun Alan Wei; Biao Si; Xiaoqian Ge; Meng Zhu; Maria A Cetatoiu; Chenze Tian; Lixin Sun; Bin Qiao
Journal:  Cardiovasc Eng Technol       Date:  2021-04-30       Impact factor: 2.495

10.  Optimism despite profound uncertainty: school and social relationships in adolescents with single ventricle heart disease.

Authors:  Jennifer K Peterson; Ellen F Olshansky; Yuqing Guo; Lorraine S Evangelista; Nancy A Pike
Journal:  Cardiol Young       Date:  2020-11-12       Impact factor: 1.093

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.